Table 3. Number and percentage of patients with positive breast cancer and brain metastasis for the molecule tested and changes in profile from breast primary to brain metastasis.
| Molecule | Number and % of breast tumours positive | Number and % of brain metastases positive | Number of breast positive to brain negative (% of breast positives changing) | Number of breast negative to brain positive (% of breast negatives changing) | ||
|---|---|---|---|---|---|---|
| ER | 15 (37%) | 18 (44%) | 0 | (0%) | 3 | (12%) |
| PR | 6 (15%) | 7 (17%) | 0 | (0%) | 1 | (3%) |
| HER2 | 13 (32%) | 17 (41%) | 1 | (8%) | 5 | (18%) |
| EGFR | 24 (59%) | 29 (71%) | 1 | (4%) | 6 | (35%) |
| IGF1 | 29 (71%) | 38 (93%) | 3 | (10%) | 12 | (100%) |
| IGF1R | 37 (90%) | 38 (93%) | 3 | (8%) | 4 | (100%) |
| TGFβ | 40 (98%) | 40 (98%) | 1 | (3%) | 1 | (100%) |
| P27kip1 | 21 (51%) | 31 (76%) | 5 | (24%) | 15 | (75%) |
| Cyclin D1 | 18 (44%) | 27 (66%) | 3 | (17%) | 12 | (52%) |
| VEGFA | 0 (0%) | 0 (0%) | 0 | (0%) | 0 | (0%) |
| VEGFR2 | 40 (98%) | 40 (98%) | 1 | (3%) | 1 | (100%) |
Abbreviations: EGFR=epidermal growth factor receptor; ER=oestrogen receptor; IGF1=insulin-like growth factor 1; IGF1R=insulin-like growth factor 1 receptor; NA=not applicable; PR=progesterone receptor; TGFβ=transforming growth factor-β; VEGFA=vascular endothelial growth factor A; VEGFR2=vascular endothelial growth factor receptor 2.